- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03984058
Recruitment Strategies Comparing Different Strategies in Sleep Apnea and Prediabetes
Comparing Recruitment Strategies for a Randomized Controlled Trial in Sleep Apnea and Prediabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Department of Medicine, Johns Hopkins University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Prediabetes: A1c value of 6.0-6.4% and fasting glucose of 100-125 mg/dl
- Moderate-to-severe OSA [4% oxygen desaturation index (ODI) ≥ 20/h]
- Ability to provide informed consent
- Able to comply with all study procedures and be available for the study duration
- Availability of smart phone
Exclusion Criteria:
- BMI < 28 or ≥ 38 kg/m2
- Type 1 or Type 2 diabetes mellitus
- Pregnancy
- Use of glucose-lowering or weight loss medications (e.g., metformin, orlistat, phentermine)
- Prior or anticipated bariatric surgery
- Current use of PAP or oral appliance therapy for OSA
- Commercial driver
- Report of a motor vehicle accident or near-miss due to sleepiness within 2 years
- Epworth Sleepiness Scale score10 > 18
- Current (prevalent) use of oral corticosteroids (within 1 month)
- Participation in a concurrent clinical trial
- Unstable medical conditions: uncontrolled angina and/or congestive heart failure, uncontrolled blood pressure or resistant hypertension [BP ≥ 160/100 among those with hypertension, requiring 3 or more meds], severe chronic obstructive pulmonary disease, cancer, or active psychiatric disease
- Other sleep disorders (e.g., circadian rhythm disorder, working night or rotation shift, short sleep duration based on self-reported habitual sleep patterns < 5 hrs/night)
- Use of supplemental oxygen during wakefulness or sleep
- Central sleep apnea (central apnea index ≥ 5/h) or Cheyne-Stokes respiration (> 10 minutes of continues period breathing) on the screening home sleep test Resting awake SpO2 < 90%
- Chronic opiate use.
- Use of illicit drug / marijuana use more than once per week
- Difficulty understanding or speaking English
- Anything that, in the opinion of the site investigator, would place the participant at increased risk or preclude a participant's ability to adhere to study protocols or complete the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Study Arm 1
All enrolled participants will have participants' PAP usage monitored by Fusion Health using the ResMed AirView Remote Monitoring system.
Fusion Health will provide individual care for each participant by monitoring daily PAP usage by all study participants.
This assessment ensures routine follow-up of PAP adherence during the study.
The responsibility for patient care during the study, however, will fall on clinical site staff with any needed assistance by the Fusion Health staff.
An intervention will be required when PAP adherence decreases or if any other issues are identified that require a face-to-face visit.
|
A lifestyle intervention program adapted from the Diabetes Prevention Program (DPP).
Study participants will start lifestyle intervention on the day of initiating PAP therapy.
The 3-month program will be followed: Patient-facing Online Platform: The program will be accessible to study participant via the Web or a Web application available for the Android and iOS devices.
Behavioral Weight Loss Goals and Lessons: The program begins with an introductory session that presents the basic goals for the program followed by 12 weekly multimedia lessons.
Submission of self-monitoring data: Participants will submit daily weight, caloric intake, and physical activity minutes at least weekly to the study website for 12 weeks.
Automated Feedback: In response to the self-monitoring data, participants receive a weekly automated message that compares participants' self-reported values to participants' goals for weekly and overall weight loss, caloric intake, and physical activity minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recruitment Yield as assessed by number of participants enrolled from electronic medical records (EMR)
Time Frame: 1 year
|
Determine recruitment yield from EMR versus the general community.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence to Pap Therapy as assessed by the ResMed AirView Remote Monitoring system
Time Frame: 1 Week
|
Participants will have PAP usage monitored with the ResMed AirView Remote Monitoring system. An intervention will be required when PAP adherence decreases or if any other issues are identified that require a face-to-face visit. A phone contact or in-person visit will be scheduled if the following findings observed for ≥3 consecutive nights:
Each participant will have a follow-up visit ~ 7 days after starting PAP therapy |
1 Week
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Naresh Punjabi, M.D., Johns Hopkins University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Glucose Metabolism Disorders
- Metabolic Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Respiration Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Neurologic Manifestations
- Endocrine System Diseases
- Diabetes Mellitus
- Signs and Symptoms, Respiratory
- Hyperglycemia
- Sleep Apnea Syndromes
- Sleep Apnea, Obstructive
- Sleep Wake Disorders
- Apnea
- Prediabetic State
- Glucose Intolerance
Other Study ID Numbers
- IRB00199862
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Disorder
-
Matrouh UniversitySuez Canal University; Beni-Suef University; University of Bisha, Saudia ArabiaCompletedSleep Disorder | Sleep Hygiene | Sleep Disorder; Insomnia Type | Sleep Disorder in Elderly | Sleep Disorder, Mental Health | Sleep Disorders, Physical HealthEgypt
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)CompletedSleep Disorder | Diarrhea | Anxiety Disorders | Insomnia | Sleep Initiation and Maintenance Disorders | Anxiety | Sleep Disturbance | Gastrointestinal Dysfunction | Heartburn | Caffeine | Caffeine Withdrawal | Caffeine; Sleep Disorder | Caffeine Dependence | Caffeine-Induced Anxiety Disorder | Caffeine-Induced Sleep... and other conditionsUnited States
-
Johannes Gutenberg University MainzRecruitingSleep Disorder | Restless Legs Syndrome | Insomnia | Sleep Apnea | Narcolepsy | Idiopathic Hypersomnia | Somnambulism | Sleep Disorder Parasomnia | REM Behavior DisorderGermany
-
Yale UniversityCompletedCircadian Rhythm Sleep Disorder, UnspecifiedUnited States
-
The University of Texas Health Science Center,...Active, not recruitingRapid Eye Movement Sleep Behavior DisorderUnited States
-
Merck Sharp & Dohme LLCCompletedDyssomnias | Sleep Disorders | Mental Disorder | Sleep Initiation and Maintenance Disorder; Elderly | Sleep Disorder, Intrinsic
-
Vanda PharmaceuticalsRecruitingSleep Disorder | Sleep Disturbance | Autism Spectrum Disorder | Neurological DisorderUnited States
-
Assistance Publique Hopitaux De MarseilleAix Marseille UniversitéRecruitingREM Sleep Behaviour DisorderFrance
-
Yale UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCritical Illness | Sleep Deprivation | Circadian Rhythm Sleep Disorder, UnspecifiedUnited States
-
Massachusetts General HospitalRecruitingRapid Eye Movement Sleep Behavior DisorderUnited States
Clinical Trials on Lifestyle Intervention
-
Sheba Medical CenterD-Cure, Israel; Chief Scientist, The Israel Ministry of ScienceCompleted
-
Northwestern UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedHyperglycemia | Glucose Metabolism Disorders | Metabolic Diseases | Obesity | Diabetes Mellitus | Endocrine System Diseases | Overnutrition | Nutrition Disorders | Overweight | Body Weight | Signs and SymptomsUnited States
-
Baylor College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Michael... and other collaboratorsActive, not recruiting
-
Molde University CollegeNorwegian Labour and Welfare AdministrationCompletedObesity | Morbid Obesity | Work Related Illnesses | Life Style | Sick-leave
-
Mayo ClinicCompletedObesityUnited States
-
DongGuk UniversityNational Research Foundation of KoreaUnknown
-
Laval UniversityActive, not recruitingPhysical Activity | Weight Loss | Dietary Modification | BreastfeedingCanada
-
University of AdelaideCompletedInsulin Resistance | Type 2 DiabetesAustralia
-
Beth Israel Deaconess Medical CenterCenter for Nutritional Research Charitable TrustCompletedObesity | Weight GainUnited States
-
Centro de Investigacion SanitariaUniversity of Helsinki; International Diabetes FederationCompletedGlucose Metabolism Disorders | Type 2 DiabetesColombia